Other Events ·
Quantum BioPharma signs contract with Thermo Fisher to implement Phase 2 Lucid-MS trial in multiple sclerosis
QNTMQuantum Biopharma Ltd.
Quantum BioPharma has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, an investigational neuroprotective therapy for progressive multiple sclerosis. The execution of this contract marks the initiation of formal study start-up activities following FDA clearance to proceed with the randomized, double-blind, placebo-controlled study. Thermo Fisher will support the company in implementing the trial, including site activation and related clinical research services. Quantum BioPharma is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders.